Evidence map›Paper›PMID 30197512›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2018

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Roland Buhl, Carl-Peter Criée, Peter Kardos, Claus F Vogelmeier, Konstantinos Kostikas, Nadine S Lossi, Heinrich Worth

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023
    Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Observational
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Roland BuhlPulmonary Department, Mainz University Hospital, Mainz, roland.buhl@unimedizin-mainz.de.
Carl-Peter CriéeDepartment of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, Bovenden.
Peter KardosGroup Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.
Konstantinos KostikasWorldWide Medical Affairs Respiratory, Novartis Pharma AG, Basel, Switzerland.
Nadine S LossiClinical Research, Respiratory, Novartis Pharma GmbH, Nürnberg.
Heinrich WorthFacharztforum Fürth, Fürth, Germany.
Evangelisches Krankenhaus Göttingen-Weende · DEGerman Center for Lung Research · DEKlinikum Fürth · DENovartis (Germany) · DENovartis (Switzerland) · CHRed Cross Hospital · GRUniversity of Applied Sciences Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: No observational studies have evaluated the "real-world" effectiveness of dual bronchodilation comprising a long-acting β Materials and methods: DACCORD is a non-interventional, observational clinical study that recruited patients following COPD maintenance therapy initiation or change in maintenance therapy between or within therapeutic class. Given the non-interventional nature of the study, the decision to initiate or change medication had to be made by the patients' physicians prior to inclusion in DACCORD. We used a matched-pairs analysis to compare disease progression in two patient groups: those receiving dual bronchodilation vs those receiving triple therapy (each group n=1,046). Results: In two subgroups of patients matched according to a broad range of demographic and disease characteristics, over 1 year, fewer patients receiving dual bronchodilation exacerbated than those receiving triple therapy (15.5% vs 26.6%; Conclusion: In this "real-life" cohort of patients with COPD, most of whom had not exacerbated in the 6 months prior to entry, triple therapy did not seem to improve outcomes compared with dual bronchodilation in terms of either exacerbations or health status. Our analyses clearly demonstrate the potential impact of prior medication on study results, something that should be taken into account when interpreting the results even of controlled clinical trials.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsDisease ProgressionDrug Therapy, CombinationFemaleGermanyHumansMaintenance ChemotherapyMaleMatched-Pair AnalysisMiddle AgedMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic Antagonistsacute exacerbations of COPDbronchodilatorCOPDCOPD course and therapyhealth-related quality of life

Identifiers

PMID30197512
PMCPMC6113909
OpenAlexW2888549501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.